About DaC-VaP-2
Find out more about the aims of DaC-Vap-2, why they are important, and how they will be accomplished.
DaC-VaP-2 : The impact of COVID-19 vaccines in pregnancy, children and young people, and vulnerable groups .
DaC-VaP-2 aims to build upon work of the previous DaC-VaP project, by following up on topics of interests identified through its Patient Public Involvement and Engagement and professional outreach activities.
There are many questions that need to be answered about the safety and effectiveness of COVID-19 vaccines.
Building on our earlier work, we engaged with a range of patient, public, community, professional and health policy groups who told us the following questions are the most important to them:
‘What is the uptake, safety and effectiveness of COVID-19 vaccines’ for the following groups:
-
in pregnancy;
-
in children and young people;
-
when given as booster doses;
-
on disease caused by different variants.
We will research the answers to these questions, within each of the four nations and the UK as a whole.
This work will help to increase the confidence of the public in the COVID-19 vaccines, by addressing questions that are of great interest. These questions (see above) were identified by engaging with patients, members of the public and decision makers.
We will continue to work with the UK’s Chief Medical Officers, Chief Scientific Advisers, and government and vaccine bodies—in particular, the Joint Committee on Vaccination and Immunisation, and the Medicines and Healthcare products Regulatory Agency—so they are aware of our work and they will be ready to use our results to inform national decisions that benefit the public.
Our research will use linked datasets from across the UK.
These will include general practitioner, vaccination, testing, viral sequencing, hospitalisation and death data.
Trained, approved data analysts will have access to the data in secure and safe settings. This means people can be confident that health data is being accessed securely and privacy protected.
By doing this, we will be able to replicate findings in different national data sources and pool results on up to 55 million people across the UK.
For more information, visit the following webpages:
EAVE II data (Scotland)
Honest Broker Service (Northern Ireland)
Royal College of General Practitioners Research and Surveillance Centre (England)
SAILBANK Database (Wales)